• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting

    5/28/25 7:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BYSI alert in real time by email

    FLORHAM PARK, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster presentation on 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) and BeyondSpring in 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 30 through June 3 in Chicago, IL.

    ​​Presentation details are as follows:

    • Title: Phase 2 Study of Pembrolizumab (Pembro) plus Plinabulin (Plin) and Docetaxel (Doc) for Patients (Pts) with Metastatic NSCLC after Progression on First-line Immune Checkpoint Inhibitor Alone or Combination Therapy: Initial Efficacy and Safety Results on Immune Re-sensitization
    • Presenter / Author : Yan Xu, Minjiang Chen, Xiaoxing Gao, Xiaoyan Liu, Jing Zhao, Wei Zhong, RuiLi Pan, Mengzhao Wang
    • Presentation Time: Saturday, May 31, 2025, at 1:30PM to 4:30PM CDT
    • Location: McCormick Place Convention Center
    • Session / Track: Lung Cancer – Non-Small Cell Metastatic
    • Abstract Number: 8560
    • Poster Board Number: 40



    About BeyondSpring

    BeyondSpring (NASDAQ:BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies for high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC and a range of cancer indications. Plinabulin's novel mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to resensitizing tumors to checkpoint inhibitors. Learn more at beyondspringpharma.com.

    About 303 Study

    303 Study is an open-label, single-arm Phase 2 Study of Plinabulin plus docetaxel and pembrolizumab for previously treated patients with metastatic NSCLC and progressive disease after anti-PD-(L)1 inhibitor alone or in combination with platinum-doublet chemotherapy. This study evaluates the efficacy and safety of this triple combination and is being conducted at Peking Union Medical College Hospital, Beijing, China with Dr. Mengzhao Wang, Chief of the Department of Respiratory and Critical Care Medicine, as the principal investigator and with Merck. The sample size of the study is 47 patients and all have been enrolled. The primary endpoint is investigator-based ORR (RECIST 1.1). The secondary endpoints include PFS, OS, DoR, and safety. The regimen includes Pembrolizumab 200 mg IV every 3 weeks (Q3W) on Day 1, Docetaxel 75 mg/m2 IV Q3W on Day 1 and Plinabulin 30mg/m2 IV Q3W on Day 1 in a 21-day cycle. The study is funded by Merck's Investigator Studies Program and BeyondSpring with provision of study drug and financial support. The registration number is NCT05599789 on clinicaltrials.gov.

    Investor Contact:

    [email protected]

    Media Contact:

    [email protected]



    Primary Logo

    Get the next $BYSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BYSI

    DatePrice TargetRatingAnalyst
    12/2/2021$38.00 → $5.00Buy → Hold
    Jefferies
    12/2/2021$45.00 → $5.00Buy → Underperform
    B of A Securities
    12/1/2021Outperform → Mkt Perform
    William Blair
    12/1/2021Buy → Neutral
    H.C. Wainwright
    9/20/2021$100.00 → $65.00Buy
    HC Wainwright & Co.
    9/9/2021$50.00Outperform
    Robert W. Baird
    9/9/2021$50.00Outperform
    Baird
    8/4/2021$100.00Neutral → Buy
    HC Wainwright & Co.
    More analyst ratings

    $BYSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Kirkby Matthew

      4 - BeyondSpring Inc. (0001677940) (Issuer)

      4/23/25 9:00:36 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Huang Lan

      4 - BeyondSpring Inc. (0001677940) (Issuer)

      4/23/25 9:00:05 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Delaney Brendan

      4 - BeyondSpring Inc. (0001677940) (Issuer)

      4/23/25 8:59:42 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BYSI
    Financials

    Live finance-specific insights

    See more
    • BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones

      Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. DocetaxelPlinabulin Phase 2 Data Highlights Potential to Resensitize Tumors Progressed on PD-1/PD-L1 Inhibitors in Metastatic NSCLCSEED Therapeutics Enters into Targeted Protein Degradation Research Collaboration with Eisai with potential payment to SEED of up to $1.5 Billion and Completes $24 Million First Close of Series A-3 FinancingSEED Therapeutics' Lead Oncology Asset RBM39 Degrader Granted Rare Pediatric Disease and Orphan Drug Designations by the FDA FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI

      3/27/25 7:00:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

      FLORHAM PARK, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the current unmet medical needs and the potential of Plinabulin as a novel immunochemotherapeutic in drug combinations and updates for SEED Therapeutics on Wednesday, May 15th, 2024 at 10:00 a.m. ET. The conference call and webinar will feature presentations by Key Opinion Leaders (KOLs) Trevor M. Feinstein, M.D. (Piedmont Cancer Institute), Alberto Chiappori, M.D. (Moffitt Cancer Center), an

      5/3/24 7:00:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors

      New Clinical Data from MD Anderson Presented at the Society for Immunotherapy of Cancer's 38th Annual Meeting80% DCR (disease control rate) in non-radiated tumor with Durable Responses in Heavily Pretreated Patients in 6 different cancersFull data was presented at SITC's 38th Annual Meeting; The Company will host a call at 8:30 a.m. ET today. Dial in: 877-407-0792, conference title: Clinical Significance of Plinabulin SITC Presentation with PI Dr. Steven Lin from MD Anderson NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platfor

      11/7/23 7:00:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BYSI
    Leadership Updates

    Live Leadership Updates

    See more
    • SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors

      NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (SEED), an innovative global biotech company focused on engineering "molecular glues" and harnessing its targeted protein degradation (TPD) platform to attack previously undruggable targets, has appointed eminent international lawyer Ko-Yung Tung to its Board of Directors. SEED is a subsidiary of BeyondSpring (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. Mr. Tung has served as a director and strategic advisor to leading international corporations and advisory councils, including Eisai Co., Ltd., Hawa

      10/23/23 7:45:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors

      Former Director at Eli Lilly, HSBC and MastercardBrings Almost Five Decades of Experience in Finance, Strategy and Risk Governance NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (the "Company"), a BeyondSpring (NASDAQ:BYSI) subsidiary and global research company focused on harnessing and engineering "molecular glues," a targeted protein degradation (TPD) platform to attack previously believed undruggable targets, today announced that it has appointed Jackson Tai to its Board of Directors. Mr. Tai has most recently retired, or will soon retire, as a Non-Executive Director of Eli Lilly (after 10 years), HSBC (after 7 years), and Mastercard (after 15 years). He brings almost 5

      6/20/23 8:00:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation

      SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the appointment of Richard John Daly ("Mr. Daly") as the President of CARsgen Therapeutics Corporation, a subsidiary of the Company in the United States. Mr. Daly will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Mr. Daly will lead the CARsgen U.S. team for the international business activities of CARsgen outside of China, including clinical development, CMC operation, busin

      1/17/22 8:50:00 AM ET
      $BYSI
      $CPRX
      $OPNT
      $PALI
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $BYSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting

      FLORHAM PARK, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster presentation on 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) and BeyondSpring in 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 30 through June 3 in Chicago, IL. ​​Presentation details are as follows: Title: Phase 2 Study of Pembrolizumab (Pembro) plus Plinabulin (Pli

      5/28/25 7:00:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

      Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD‑1/L1 therapySEED's first‑in‑class RBM39 degrader, reported at AACR 2025 for its total tumor regression data in mechanism targeted cancer indication-Ewing Sarcoma, remains on track for IND filing mid‑2025 FLORHAM PARK, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a clinical‑stage global biopharmaceutical company focused on developing cancer therapeutics, today announced its unaudited financial results for the quarter ended March 31, 2025, and provided a corporate update. "Plinabulin has now been administered to more than 7

      5/12/25 4:30:44 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring Files 2024 Annual Report on Form 10-K

      FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission ("SEC") on March 27, 2025. The annual report on Form 10-K, which contains the Company's audited consolidated financial statements, can be accessed on the SEC's website at www.sec.gov and on the Company's website at www.beyondspringpharma.com under "Financials & Filings" in the Investors section. The Company will provide

      3/27/25 7:05:00 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BYSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BeyondSpring downgraded by Jefferies with a new price target

      Jefferies downgraded BeyondSpring from Buy to Hold and set a new price target of $5.00 from $38.00 previously

      12/2/21 5:17:19 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring downgraded by B of A Securities with a new price target

      B of A Securities downgraded BeyondSpring from Buy to Underperform and set a new price target of $5.00 from $45.00 previously

      12/2/21 4:49:29 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring downgraded by William Blair

      William Blair downgraded BeyondSpring from Outperform to Mkt Perform

      12/1/21 10:55:31 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BYSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BeyondSpring Inc.

      SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

      11/14/24 9:52:50 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by BeyondSpring Inc. (Amendment)

      SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

      2/14/24 4:30:59 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by BeyondSpring Inc. (Amendment)

      SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

      4/7/23 5:02:43 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BYSI
    SEC Filings

    See more
    • SEC Form 10-Q filed by BeyondSpring Inc.

      10-Q - BeyondSpring Inc. (0001677940) (Filer)

      5/12/25 4:31:17 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BeyondSpring Inc. (0001677940) (Filer)

      5/12/25 4:30:15 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by BeyondSpring Inc.

      10-K - BeyondSpring Inc. (0001677940) (Filer)

      3/27/25 7:06:20 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care